261 related articles for article (PubMed ID: 38474160)
21. Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases.
Sadeghi M; Dehnavi S; Asadirad A; Xu S; Majeed M; Jamialahmadi T; Johnston TP; Sahebkar A
Inflammopharmacology; 2023 Jun; 31(3):1069-1093. PubMed ID: 36997729
[TBL] [Abstract][Full Text] [Related]
22.
Feng L; Lu WH; Li QY; Zhang HY; Xu LR; Zang WQ; Guo WT; Li YF; Zheng WJ; Geng YX; Li Q; Liu YH
Am J Chin Med; 2023; 51(5):1189-1209. PubMed ID: 37314412
[TBL] [Abstract][Full Text] [Related]
23. Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy.
Patel DA; Patel SS; Patel HD
Bioorg Chem; 2024 Feb; 143():107045. PubMed ID: 38147786
[TBL] [Abstract][Full Text] [Related]
24. Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities.
Zang WB; Wei HL; Zhang WW; Ma W; Li J; Yao Y
Eur J Med Chem; 2024 Feb; 265():116070. PubMed ID: 38134747
[TBL] [Abstract][Full Text] [Related]
25. Exploring Monkeypox: prospects for therapeutics through computational-aided drug discovery.
Grajales DB; Kar S
Mol Divers; 2023 Dec; ():. PubMed ID: 38079063
[TBL] [Abstract][Full Text] [Related]
26. Nanotechnology and curcumin: a novel and promising approach in digestive cancer therapy.
Zhang Y; Li Z; Huang Y; Xu Y; Zou B
Nanomedicine (Lond); 2023 Nov; 18(27):2081-2099. PubMed ID: 38078442
[TBL] [Abstract][Full Text] [Related]
27. Targeting endothelial cells with golden spice curcumin: A promising therapy for cardiometabolic multimorbidity.
Tang F; Liu D; Zhang L; Xu LY; Zhang JN; Zhao XL; Ao H; Peng C
Pharmacol Res; 2023 Nov; 197():106953. PubMed ID: 37804925
[TBL] [Abstract][Full Text] [Related]
28. DYRK2 promotes chemosensitivity via p53-mediated apoptosis after DNA damage in colorectal cancer.
Takano Y; Yogosawa S; Imaizumi Y; Kamioka H; Kanegae Y; Eto K; Yoshida K
Cancer Sci; 2023 Dec; 114(12):4558-4570. PubMed ID: 37776195
[TBL] [Abstract][Full Text] [Related]
29. Modified Curcuminoid-Rich Extract Liposomal CRE-SDInhibits Osteoclastogenesis via the Canonical NF-κB Signaling Pathway.
Jantarawong S; Swangphon P; Lauterbach N; Panichayupakaranant P; Pengjam Y
Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765217
[TBL] [Abstract][Full Text] [Related]
30. Curcumin, inflammation, and neurological disorders: How are they linked?
Garodia P; Hegde M; Kunnumakkara AB; Aggarwal BB
Integr Med Res; 2023 Sep; 12(3):100968. PubMed ID: 37664456
[TBL] [Abstract][Full Text] [Related]
31. Mechanism insights of curcumin and its analogues in cancer: An update.
Joshi P; Verma K; Kumar Semwal D; Dwivedi J; Sharma S
Phytother Res; 2023 Dec; 37(12):5435-5463. PubMed ID: 37649266
[TBL] [Abstract][Full Text] [Related]
32. Nano-based formulations of curcumin: elucidating the potential benefits and future prospects in skin cancer.
Ratan C; Arian AM; Rajendran R; Jayakumar R; Masson M; Mangalathillam S
Biomed Mater; 2023 Aug; 18(5):. PubMed ID: 37582394
[TBL] [Abstract][Full Text] [Related]
33. Curcumin-based nanoformulations alleviate wounds and related disorders: A comprehensive review.
Ansari L; Mashayekhi-Sardoo H; Baradaran Rahimi V; Yahyazadeh R; Ghayour-Mobarhan M; Askari VR
Biofactors; 2023; 49(4):736-781. PubMed ID: 36961254
[TBL] [Abstract][Full Text] [Related]
34. Natural bioactive compounds-doxorubicin combinations targeting topoisomerase II-alpha: Anticancer efficacy and safety.
Elfadadny A; Ragab RF; Hamada R; Al Jaouni SK; Fu J; Mousa SA; El-Far AH
Toxicol Appl Pharmacol; 2023 Feb; 461():116405. PubMed ID: 36716865
[TBL] [Abstract][Full Text] [Related]
35. AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage.
Pei JP; Wang Y; Ma LP; Wang X; Liu L; Zhang Y; Jin R; Ren ZQ; Deng Y; Shen JK; Meng T; Yu K
Acta Pharmacol Sin; 2023 Jun; 44(6):1290-1303. PubMed ID: 36650292
[TBL] [Abstract][Full Text] [Related]
36. Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001-2021).
Bhagat K; Kumar N; Kaur Gulati H; Sharma A; Kaur A; Singh JV; Singh H; Bedi PMS
Expert Opin Ther Pat; 2022 Oct; 32(10):1079-1095. PubMed ID: 36189616
[TBL] [Abstract][Full Text] [Related]
37. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
Crocetti L; Floresta G; Cilibrizzi A; Giovannoni MP
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956914
[TBL] [Abstract][Full Text] [Related]
38. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
Front Immunol; 2022; 13():869676. PubMed ID: 35572601
[TBL] [Abstract][Full Text] [Related]
39. Flavonoids as Potential Anti-Inflammatory Molecules: A Review.
Al-Khayri JM; Sahana GR; Nagella P; Joseph BV; Alessa FM; Al-Mssallem MQ
Molecules; 2022 May; 27(9):. PubMed ID: 35566252
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic Insights and Docking Studies of Phytomolecules as Potential Candidates in the Management of Cancer.
Sharma P; Kumar D; Shri R; Kumar S
Curr Pharm Des; 2022; 28(33):2704-2724. PubMed ID: 35473540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
